Thiazolidinediones on PPAR\(\gamma\): The Roles in Bone Remodeling

Wei Wei and Yihong Wan

Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA

Correspondence should be addressed to Yihong Wan, yihong.wan@utsouthwestern.edu

Received 27 August 2011; Revised 4 October 2011; Accepted 5 October 2011

Academic Editor: Beata Lecka-Czernik

Copyright © 2011 W. Wei and Y. Wan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thiazolidinediones (TZDs) are synthetic PPAR\(\gamma\) (peroxisome proliferator-activated receptor gamma) agonists and a class of drugs for diabetes mellitus type 2 that can decrease blood sugar efficiently by enhancing insulin sensitivity. However, increased bone fracture risk in diabetic individuals treated with TZDs is one of the reported side effects. Recent studies show that TZDs such as rosiglitazone simultaneously inhibit osteoblast differentiation and activate osteoclast differentiation, leading to bone loss due to decreased bone formation and increased bone resorption. Furthermore, TZDs may activate PPAR\(\gamma\) in tissues other than bone, such as the hypothalamus-pituitary-gonad (HPG) axis to indirectly regulate bone mass. This paper will focus on current new developments that implicate potential mechanisms for how PPAR\(\gamma\) modulates skeletal homeostasis and how TZDs exert bone-loss side effects.

1. Introduction

Rather than a rigid and dormant organ that merely serves an inert support for the vertebrates, bone is a highly dynamic tissue that undergoes constant remodeling, adaptation, repair, and regeneration. Evolution has crafted the structure of the skeletal system in such an elegant way that it is light weighted so birds can fly, yet strong so cheetah can run and hunt. The quantity and quality of bone are influenced by both genetic traits and environmental factors such as nutrition, exercise, and hormone. Bone loss or osteoporosis occurs in physiological and pathological conditions such as aging, postmenopause, sedentary lifestyle, weightlessness during spaceflight, diabetes, and bone metastasis of cancers. With the extension of lifespan and changes in life style, osteoporosis and bone fractures are becoming a leading cause of morbidity and mortality in the modern society. It is estimated that an osteoporotic fracture occurs every 3 seconds worldwide [1]; one out of three women and one out of five men over 50 years of age will experience osteoporotic fractures [2–4]. Between 1990 and 2000, there was nearly a 25% increase in hip fractures worldwide [1]; by 2050, the worldwide incidence of hip fracture is projected to increase by 310% in men and 240% in women [5]. Osteoporosis takes a huge personal and economic toll, for example, in women over 45 years of age, it accounts for more days spent in hospital than many other diseases including diabetes, myocardial infarction, or breast cancer [6]. However, the great majority (>80%) of high-risk individuals are neither identified nor treated [7]. Therefore, enhanced understanding of bone biology and development of effective diagnosis, prevention, and treatment for osteoporosis are of paramount medical urgency and clinical significance.

Bone harnesses an enormous ability to repair and regenerate—both quantity and quality of the bone are maintained by an intricate cellular network composed mainly of three cell types: osteoclasts, osteoblasts, and osteocytes. Osteoclasts are bone-resorbing cells responsible for removing old bones, which are differentiated from hematopoietic progenitors of the monocyte/macrophage lineages upon activation by cytokines such as RANKL (receptor activator of nuclear factor kappa-B ligand) [8–12]. Osteoblasts are bone-forming cells responsible for generating and mineralizing new bone, which are differentiated from mesenchymal progenitors upon activation of several transcription factors such as runx2 and osterix [13–15]. Osteocytes are the most abundant cells in the bone matrix that are thought to derive from osteoblasts, and regulate numerous functions including mechanical sensing, bone remodeling, and mineral metabolism, by both physical interaction and
paracrine/endocrine signaling [16, 17]. The balance between bone resorption by osteoclasts and bone formation by osteoblasts is critical for skeletal homeostasis, and bone loss occurs when resorption outpaces formation.

2. TZDs Cause Bone Loss and Higher Fracture Rates in Diabetic Patients

Thiazolidinediones (TZDs—troglitazone, rosiglitazone, pioglitazone, and netoglitazone) are widely used for the management of diabetes mellitus type 2. On the one hand, TZDs can enhance glucose uptake, by increasing insulin-sensitivity of adipocytes, muscle, liver, macrophages, and so forth; on the other hand, TZDs can also inhibit gluconeogenesis in the liver, both resulting in decreased insulin resistance and lower blood sugar levels [18, 19]. However, as a common sense, drugs are often accompanied with side effects and TZDs is not an exception. In addition to side effects such as weight gain and fluid retention, increasing reports indicate that both rosiglitazone and pioglitazone are associated with a higher fracture risk. With 4 years of rosiglitazone treatment, type 2 diabetic patients in ADOPT (A Diabetes Outcome Progression Trial) showed increased incidence of fractures in women [20]. Similarly, pioglitazone is also reported to have the same side effect [21]. Moreover, by taking paired stored baseline and 12-month serum samples from 1605 participants (689 women, 916 men) in ADOPT, a recent study showed that CTX-1 (C-terminal telopeptide for type 1 collagen), a marker for osteoclast activity and bone resorption, was increased by 6.1% in the rosiglitazone-treated group in women but not men; P1NP (procollagen type 1 N-propeptide) and bone alkaline phosphatase, two markers for osteoblast activity and bone formation, were decreased in both women and men treated with rosiglitazone [22]. This indicates that elevated bone resorption and suppressed bone formation are important mechanisms that contribute to the bone loss side effects and the higher fracture risk in women taking TZDs [22].

Importantly, emerging evidence indicates that metabolic state may influence the effects of TZDs on bone [23]. For example, epidemiological studies suggest that skeletal fragility is already increased in type 2 diabetes mellitus [24, 25], potentially due to the inhibition of osteoblast differentiation and function by hyperglycemia-associated ROS (reactive oxygen species) accumulation and/or glucose toxicity [26–28]. Thus, rosiglitazone-induced bone loss may be exacerbated in diabetic patients compared with healthy individuals. An important question for future study is whether and how different metabolic states such as obesity, diabetes, insulin resistance, and aging modulate the relative effects of TZDs on bone resorption versus formation. The purpose of this review is to survey in vivo and in vitro evidence supporting direct and indirect effects of TZDs on osteoclasts and osteoblasts, thus proposing hypotheses for future investigations (Figure 1).

3. PPARγ Regulates Osteoblastogenesis and Osteoclastogenesis

PPARγ (peroxisome proliferator-activated receptor gamma) is a member of the nuclear receptor superfamily of transcription factors that can be activated by lipophilic ligands [29]. Upon ligand activation, PPARγ typically induces target gene expression by binding to PPAR response elements (PPREs) in the promoter regions as a heterodimer with the retinoid X receptor (RXR) and recruiting transcription coactivators [29]. Accumulating evidence demonstrates that PPARγ functions as a key regulator of skeletal homeostasis by directly regulating the differentiation of bone cells.

It has been first reported that PPARγ exerts negative effects on osteoblast differentiation and bone formation. Homozygous PPARγ-deficient embryonic stem cells failed to differentiate into adipocytes, but spontaneously differentiated into osteoblasts; heterozygous PPARγ-deficient mice exhibited high bone mass, resulting from enhanced osteoblastogenesis from bone marrow mesenchymal stem cells but reduced adipogenesis [30]. Consistently, PPARγ activation by TZD treatment inhibits osteoblast differentiation but promotes adipocyte differentiation [31–33]. Moreover, recent evidence has revealed that TZDs may also negatively impact bone by inducing osteocyte apoptosis and the expression...
of sclerostin, a Wnt antagonist and an inhibitor of bone formation [34, 35].

Subsequently, PPARy has been found to also enhance RANKL-mediated osteoclast differentiation from hematopoietic stem cells [36]. PPARy deletion in mouse hematopoietic lineages caused osteoclast deficiency, leading to osteoporosis manifested as high bone mass and extramedullary hematopoiesis in the spleen, as well as resistance to rosiglitazone-stimulated bone resorption [36]. At molecular level, PPARy activation by rosiglitazone suppresses β-catenin protein levels and function [37, 38], induces the expression of PGC1β (peroxisome proliferator-activated receptor gamma coactivator 1-beta), and potentiates RANKL-induced transcription of c-fos, an essential mediator of osteoclastogenesis [36, 37]. Interestingly, growing evidence suggest that osteoclastogenesis may occur via the canonical pathways in which RANKL can be substituted by other growth factors such as TNFα, LIGHT (TNFSF14), IL-6, TGFβ, APRIL, BAFF, NGF, IGF-I, or IGF-II [39–46]. In future studies, it would be important to determine the effects of TZD treatment on the osteoclastogenesis mediated by these RANKL-independent pathways.

Pharmacologically, recent clinical trials report that long-term use of TZDs, such as rosiglitazone, increases fracture rates among diabetic patients [20, 22, 24, 47, 48]. Using animal models such as mice and rats, numerous studies show that TZDs cause bone loss by simultaneously decreasing bone formation and increasing bone resorption, thus uncoupling of bone remodeling [23, 31, 36, 37, 49, 50]. Together, these findings indicate that TZD-induced skeletal fragility is mainly achieved by bone cell-autonomous PPARy activation, which inhibits osteoblastogenesis and enhances osteoclastogenesis.

4. OPG/RANKL in Osteoclastogenesis

The cytokines RANKL (receptor activator of nuclear factor NF-κB ligand) and MCSF (macrophage colony stimulating factor) are required for the differentiation from osteoclasts progenitors into mature osteoclasts. MCSF functions through its receptor MCSFR (c-fms) to promote macrophage/osteoclast precursor proliferation and survival. Upon binding to its receptor RANK, RANKL activates several key transcription factors such as c-fos, c-jun, NFATc1 (nuclear factor of activated T cells, cytoplasmic 1), and NF-κB, as well as osteoclastic enzymes such as TRAP (tartrate-resistant acid phosphatase) and CTSK (cathepsin K), which concertedly trigger the differentiation, multinucleation, maturation, and activation of osteoclasts [12, 51]. As a counter balance, osteoprotegerin (OPG) is a naturally occurring decoy receptor for RANKL, thereby inhibiting osteoclastogenesis and bone resorption [51]. Selectively blocking OPG will increase RANKL activity and osteoclastogenesis, leading to osteoporosis eventually. Both RANKL and OPG are secreted from osteoblasts to regulate osteoclast differentiation; therefore, RANKL/OPG ratio is a critical factor that regulates the balance between osteoblasts and osteoclasts, thus the coupling between bone formation and resorption.

In addition to PPARy expressed endogenously in the osteoclasts, PPARy in other cell types have also been shown to indirectly influence osteoclastogenesis. It has been implicated that PPARy activation in osteoblast or adipocytes may promote osteoclast differentiation by inducing the expression of RANKL [23, 52]. Another recent study reported that osteoblast-specific overexpression of PPARy led to lower bone mass in male mice and accelerated ovariotomy-induced bone loss in female mice, associated with not only decreased bone formation but also increased RANKL/OPG ratio [53]. These studies further support the notion that TZDs-induced skeletal fragility is mediated by multifaceted actions of PPARy on both osteoblast and osteoclast, via both cell-autonomous and paracrine regulations.

Interestingly, recent studies have reported that TZDs can also affect systemic OPG levels. After 24 weeks of treatment of pioglitazone or metformin in 67 type 2 diabetic patients, it was found that plasma levels of OPG decreased in the pioglitazone group, but were unchanged in the metformin group [54]. A similar study showed that comparing 46 type 2 diabetic patients treated with TZDs with 152 type 2 diabetic patients receiving other oral antidiabetes drugs, TZDs treatment is associated with a decrease in plasma OPG levels [55]. Besides in vivo, PPARy agonists have also been shown to downregulate OPG levels in vitro. Troglitazone can decrease OPG concentration in a dose-dependent manner in 8-day-cultured human mesenchymal stem cells (hMSCs); on the contrary, PPARy inhibitor GW9662 can enhance early OPG protein levels by hMSCs [56]. Together, these studies have identified RANKL and OPG as potential contributing factors for the enhanced osteoclastogenesis and bone resorption associated with TZDs, suggesting that pharmacological reduction of the RANKL/OPG ratio may be novel strategies to combat TZD-induced bone loss.

5. Sex Hormone Receptors and Osteoclast Survival

Estrogen is osteoprotective, and estrogen decline plays an important role in postmenopausal osteoporosis. First, estrogen is implied to decrease the osteoclastic resorption pit in bone by regulating several transcription factors (c-fos, c-jun, e.g.) and inflammatory cytokines (IL-1RI, IL-1RII, e.g.) [57]. Second, our recent study reveals that estrogen loss in mice by ovariectomy stimulates osteoclast progenitors to proliferate and differentiate; suggesting estrogen also inhibits osteoclastogenesis in vivo [58]. Third, estrogen has been shown to promote osteoclast apoptosis [59, 60]. This suggests that estrogen antagonizes osteoclast differentiation and function, and potentially suppresses PPARy-stimulated osteoclastogenesis. Consistently, estrogen has been shown to be protective against TZD-induced bone loss, for example, TZD-induced bone loss is more significant in postmenopausal women [22, 61, 62]; estrogen significantly reduces TZD-induced adipogenesis [63], osteocyte apoptosis, and sclerostin upregulation [34]. Interestingly, a recent study shows that TZDs (rosiglitazone or pioglitazone) also inhibit estrogen synthesis.
in human granulosa cells by interfering with androgen binding to aromatase, thus directly affecting estrogen production in human ovarian cells [64]. Together, these findings suggest another potential contributing mechanism for TZD-induced osteoclast activation and bone loss, which may involve the suppression of estrogen function and/or production. In future investigations, it would be important to further examine the in vivo effects of TZDs on estrogen synthesis and activity in animal models and in clinical trials.

Among the two estrogen receptor isoforms (ERα and ERβ), ERα is mainly responsible for estrogen regulation of osteoclast survival [60]. ERα diminishes mature osteoclast lifespan through the induction of the proapoptotic Fas ligand (Fasl) [60]. Selective deletion of ERα in differentiated osteoclasts in the ERαΔOc/ΔOc female mice led to a lower bone mass, mimicking the postmenopausal osteoporosis in women [60]. In contrast, in the functional Fasl knockout mice (FasLgld/gld), neither enhanced bone resorption nor bone loss was induced by osteoclastic ERα deficiency [60]. Thus, in differentiated osteoclast, Fasl expression appears to be positively controlled by activated ERα. In addition to the role for Fasl in estrogen-induced osteoclast apoptosis by an autocrine mechanism involving osteoclasts alone [60], another study has proposed a paracrine mechanism in which estrogen affects osteoclast survival through the upregulation of FasL in osteoblasts (and not osteoclasts) leading to the apoptosis of preosteoclasts [59].

A recent study has shown that in two hormone-dependent breast cancer cell lines (MCF-7 and ZR-75-1), PPARγ activation could lead to ERα downregulation through the proteasome-dependent degradation pathway [65]; yet different PPARγ agonists exerted differential effects on ERα stability: troglitazone, ciglitazone, and natural PPARγ ligand 15d-PGJ(2) induced ERα degradation efficiently while rosiglitazone did not alter ERα protein levels [65]. Interestingly, another recent study has shown that in MCF7 cells, rosiglitazone could increase the transactivation of FasL promoter through Sp1 site in a dose-related and PPARγ-dependent manner, which could be abrogated by PPARγ antagonist GW9662 [66]. It concludes that PPARγ triggers apoptotic events in breast cancer cells via Fas/FasL signaling pathway [66]. In osteoclasts, the effects of PPARγ activation on ERα degradation and Fasl expression are underexplored, thus begging the question whether TZDs promote osteoclast survival by reducing ERα protein, or promote osteoclast apoptosis by inducing Fasl mRNA. Therefore, to determine how PPARγ regulates osteoclast activity, it would be important to investigate both cell-autonomous effects of TZDs on ERα/Fasl pathway and osteoclast survival; as well as systemic effects of TZDs on estrogen production and its induction of osteoclast apoptosis.

In addition to ERα, there are other transcription factors that potentially regulate the functions of estrogen. For example, the orphan nuclear receptor estrogen-related receptor α (ERRα) has been shown to regulate many of the same genes as ERα [67, 68], and modulate the activity of ERα in various tissues including breast, uterus, and bone [69]. ERRα has been shown to be involved in the control of not only energy metabolism but also skeletal homeostasis. The roles of ERRα in osteoblastogenesis are being actively investigated, and conflicting results have been reported that ERRα can either activate or inhibit osteoblast differentiation [70]. Furthermore, our recent study reveals another novel function for ERRα in enhancing osteoclastogenesis by inducing the expression of mitochondrial genes via a PGC1β-dependent pathway [37]. Induced by PPARγ and coactivated by PGC1β, ERRα not only promotes mitochondrial activation but also increase osteoclast differentiation [12, 37]. On the one hand, reactive oxygen species (ROS), released from mitochondria, can stimulate osteoclast differentiation by promoting Ca^{2+} oscillations and NFATc1 activation; on the other hand, several transcription factors induced during osteoclastogenesis can activate the expression of target genes required for mitochondrial biogenesis [12, 37, 71]. Consequently, ERRα knockout mice exhibit decreased osteoclasts number, bone resorption, and higher bone mass [37]. Because of the crucial role of estrogen deficiency in postmenopausal osteoporosis, it will be interesting in future studies to determine whether and how the PPARγ/PGC1β/ERRα pathway interacts with the ER signaling in bone remodeling.

6. Hypothalamic-Pituitary-Gonadal (HPG) Axis and Bone Remodeling

Although TZDs have been shown to modulate skeletal homeostasis by directly activating PPARγ in bone cells and regulating osteoblast/osteoclast differentiation, new evidence implies that TZDs may also function indirectly through PPARγ in other tissues such as the hypothalamus. A recent study has unveiled an unknown role for central nervous system (CNS) PPARγ in the regulation of energy balance [72]: both acute and chronic activation of CNS PPARγ by either TZDs or hypothalamic overexpression of a fusion protein consisting of PPARγ and the viral transcriptional activator VP16 (VP16-PPARγ), led to positive energy balance in rats, including cumulative food intake and body fat gain. Blocking the endogenous activation of CNS PPARγ with pharmacological antagonists or reducing its expression with shRNA led to negative energy balance, restored leptin sensitivity in high-fat-diet-fed rats and blocked the hyperphagic response to oral TZD treatment [72]. These findings implicate a provocative hypothesis to be tested in future studies that CNS PPARγ may also contribute to the regulation of bone mass by TZDs, potentially via the hypothalamic-pituitary-gonadal (HPG) relay.

The classic theory predicts that sex steroid (estrogen and androgen) deficiency is the main cause of osteoporosis; however, emerging evidence indicate that other hormones in the hypothalamic-pituitary-gonadal (HPG) axis also participate in the maintenance of bone homeostasis [73]. Progesterone, normally modulated by estrogens, is a female hormone important for the regulation of ovulation, pregnancy, and menstruation. It has been shown that progesterone increases osteoblasts numbers and promotes osteoblasts differentiation and maturation, which is independence of estrogen [74]. Another recent study has reported that the osteoclast differentiation factor RANKL functions as
an important in vivo molecular link between progesterone and epithelial carcinogenesis by controlling the incidence and onset of progesterone-driven mammary cancer [75]. This suggests that progesterone may also regulate RANKL-induced osteoclastogenesis. Concerning PPARγ, its agonist, rosiglitazone, can generally antagonize progesterone activity by stimulating progesterone receptor (PR) B degradation and blocking progesterone-induced PRB phosphorylation [76]. Together, these findings suggest that PPARγ regulation of bone homeostasis may be also partially mediated by modulating progesterone function, which remains to be further investigated in future studies.

Activin and inhibin, two closely related protein complexes secreted from the gonad, are members of the transforming growth factor beta (TGFβ) family, which controls cell proliferation and differentiation in many organs. Activin is either a homodimer composed of two identical βA (activin A) or βB (activin B) subunits or a heterodimer of βA and βB (activin AB); inhibin is a heterodimer comprised of αβA (inhibin A) and αβB (inhibin B) subunits, and α subunit is unique to inhibin. Activin and inhibin exert opposite biological effects in a variety of cell types. For examples, activin enhances whereas inhibin suppresses follicle-stimulating hormone (FSH) biosynthesis and secretion from the anterior pituitary [77]. Cellular and physiological evidence show that both activins and inhibins regulate osteoblastogenesis and osteoclastogenesis, thus modulating bone mass in vivo [78]. Interestingly, PPARγ has been reported to crosstalk with activin A: on the one hand, activin A treatment can inhibit PPARγ expression in 3T3-L1 preadipocytes, leading to reduced adipocytes differentiation [79]; on the other hand, PPARγ activation by rosiglitazone can decrease follistatin (activin A antagonist) mRNA levels in rat intestinal epithelial cells, leading to the gain-of-function of activin A, which mediates the effects of TZDs on cell proliferation [80]. These results suggest that PPARγ may also interact with the activin/inhibin pathways to regulate bone remodeling, which represents another important future direction for investigation.

Follicle-stimulating hormone (FSH), derived from pituitary, has been proposed to regulate bone mass via several controversial and contradictory mechanisms. In perimenopausal women, increase of serum FSH, but not loss of estrogen, has been reported to better correlate with bone turnover and/or BMD across the menopause transition [81–83]. It has been shown that FSH enhances osteoclastogenesis by activating MEK/Erk, NF-κB, and Akt; furthermore, FSHβ KO mice and FSH receptor (FSHR) KO mice are resistant to bone loss despite severe hypogonadism; FSHββ−/− mice exhibit increased bone mass and decreased osteoclastic resorption with normal ovarian function, suggesting that the skeletal action of FSH is estrogen independent [84]. In contrast, two recent reports have provided opposite evidence. First, in a prospective clinical study, it has been found that suppression of FSH secretion by a GnRH agonist failed to reduce bone resorption markers in postmenopausal women [85]. Second, using FSH transgenic mice, it has been shown that FSH has dose-dependent anabolic (rather than catabolic) effects on bone, via an ovary-dependent and nonbone-cell-autonomous mechanism [86]. PPARγ is highly expressed in the pituitary [87]. It has been reported that PPARγ and TZDs can alter the secretion and function of pituitary hormones. For examples, pituitary-specific deletion of PPARγ increases luteinizing hormone (LH) levels in female mice and decreases FSH levels in male mice [88]; TZD activation of PPARγ inhibits LH secretion [89] and gonadotropin-releasing hormone (GnRH) signaling [88]. Together, these reports warrant future investigations on the hypothesis that TZDs may partially exert its effects on bone by regulating hormones in the HPG axis such as GnRH, LH, and FSH.

Oxytocin is another pituitary hormone related to the bone homeostasis. Oxytocin has been shown to regulate the differentiation outcome of mesenchymal stem cells by trending toward osteoblasts but inhibiting adipocytes [90]. As oxytocin receptor is expressed and functional in human osteocytes [91], the possibility exists that oxytocin modulates bone mass by also regulating osteoclastogenesis. Clinically, it is shown that plasma oxytocin levels are significantly lower in postmenopausal women developing osteoporosis than in their healthy counterparts [90]. Mechanically, oxytocin increases bone morphogenetic protein 2 (BMP2) expression, consequently upregulates the functions of Schnurri-2 and 3, Osterix, and ATF-4, all of which are known activators of osteoblastogenesis [92]. Interestingly, PPARγ has been shown to also crosstalk with oxytocin signaling: in contrast to the aforementioned report [90], oxytocin was reported to stimulate adipocytes differentiation by increasing expression of PPARγ, fatty acid binding protein (FABP), insulin-sensitive glucose transporter 4 (GLUT4), leptin, and CD31 in the epididymal and/or retroperitoneal fat tissue of oxytocin-treated rats [93]. Similar to oxytocin, as another pituitary hormone, prolactin also regulates bone remodeling. In osteoblast-like cells, MG-63, prolactin inhibits osteoblastogenesis and promotes osteoclastogenesis by increasing the ratio of RANKL/OPG [94]. Prolactin signaling has also been shown to interact with PPARγ pathway. On the one hand, prolactin enhances PPARγ and C/EBPβ mRNA production and augments adipocytes differentiation in NIH-3T3 cells [95]; on the other hand, TZDs activation of PPARγ inhibits prolactin function in pituitary tumor cells [96]. These observations suggest that the effects of TZD and PPARγ on bone remodeling may be also modulated by pituitary hormones such as oxytocin and prolactin, which needs to be further examined in both animal models and clinical investigations in the future.

7. Concluding Remarks

In light of the vast array of potential target tissues, pharmacological and mechanistic understanding of cell type-specific gene regulation by PPARγ and TZDs will help to design improved diabetic drugs, such as selective PPARγ modulators, which retain high potency to treat diabetes with minimal bone loss side effects [12, 97]. By using ligands with distinct chemical structures, it has been shown that different PPARγ functions could be separated. Unlike other TZDs,
netoglitazone (MCC-555, RWJ-241947) serves as an example of a selective PPARγ modulator that can distinguish the antosteoblastogenic and proadipogenic functions of PPARγ; mice treated with netoglitazone showed decreased glucose levels similarly to rosiglitazone, but without bone loss [98]. Moreover, a recent study reveals that the proadipogenic effects and insulin-sensitizing effects of PPARγ can be separated using partial agonists that selectively block cdk5-induced PPARγ phosphorylation [99]. As an alternative strategy to improve the outcome of TZD treatment by lessening the side effects, combination therapies haven been used. A recent report suggests that TZD/metformin combination therapy is associated with less weight gain than TZD monotherapy [100]. Thus, if used together with bone anabolic and/or anticatabolic drugs, the TZD-mediated bone loss side effects may be dampened. More provocatively, because PPARγ acts as a double-edged sword to not only inhibit bone formation but also promote bone resorption, bone-specific PPARγ antagonists may represent a potential new therapeutic strategy for the simultaneous anabolic and anticatabolic treatment of osteoporosis.

Conflict of Interests
The authors declare that they have no financial conflict of interest.

Acknowledgments
The authors thank all the investigators whose studies contributed to the understanding of PPARγ and TZD actions but could not be cited here because of space limitations. Y. Wan is a Virginia Murchison Linthicum Scholar in Medical Research. This paper was supported by the University of Texas Southwestern Medical Center Endowed Scholar Startup Fund, a BD Biosciences Research Grant Award, CPRIT (RP100841), March of Dimes (no. 5-FY10-1), The Welch Foundation (I-1751), and NIH (R01 DK089113).

References

[1] O. Johnell and J. A. Kanis, “An estimate of the worldwide prevalence and disability associated with osteoporotic fractures,” Osteoporosis International, vol. 17, no. 12, pp. 1726–1733, 2006.

[2] L. J. Melton III, E. J. Atkinson, M. K. O’Connor, W. M. O’Fallon, and B. L. Riggs, “Bone density and fracture risk in men,” Journal of Bone and Mineral Research, vol. 13, no. 12, pp. 1915–1923, 1998.

[3] L. J. Melton III, E. A. Chrischilles, C. Cooper, A. W. Lane, and B. L. Riggs, “Perspective: how many women have osteoporosis?” Journal of Bone and Mineral Research, vol. 7, no. 9, pp. 1005–1010, 1992.

[4] J. A. Kanis, O. Johnell, A. Oden et al., “Long-term risk of osteoporotic fracture in Malmo,” Osteoporosis International, vol. 11, no. 8, pp. 669–674, 2000.

[5] B. Gullberg, O. Johnell, and J. A. Kanis, “World-wide projections for hip fracture,” Osteoporosis International, vol. 7, no. 5, pp. 407–413, 1997.

[6] J. A. Kanis, P. Delmas, P. Burckhardt et al., “Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease,” Osteoporosis International, vol. 7, no. 4, pp. 390–406, 1997.

[7] T. V. Nguyen, J. R. Center, and J. A. Eisman, “Osteoporosis: underrated, underdiagnosed and undertreated,” Medical Journal of Australia, vol. 180, supplement 5, pp. S18–S22, 2004.

[8] W. J. Boyle, W. S. Simonet, and D. L. Lacey, “Osteoclast differentiation and activation,” Nature, vol. 423, no. 6937, pp. 337–342, 2003.

[9] J. R. Edwards and G. R. Mundy, “Advances in osteoclast biology: old findings and new insights from mouse models,” Nature Reviews Rheumatology, vol. 7, no. 4, pp. 235–243, 2011.

[10] D. V. Novack and S. L. Teitelbaum, “The osteoclast: friend or foe?” Annual Review of Pathology, vol. 5, pp. 457–484, 2008.

[11] S. L. Teitelbaum and F. P. Ross, “Genetic regulation of osteoclast development and function,” Nature Reviews Genetics, vol. 4, no. 8, pp. 638–649, 2003.

[12] Y. Wan, “PPARγ in bone homeostasis,” Trends in Endocrinology and Metabolism, vol. 21, no. 12, pp. 722–728, 2010.

[13] G. Karsenty, “Transcriptional control of skeletogenesis,” Annual Review of Genomics and Human Genetics, vol. 9, pp. 183–196, 2008.

[14] A. G. Robling, A. B. Castillo, and C. H. Turner, “Biomechanical and molecular regulation of bone remodeling,” Annual Review of Biomedical Engineering, vol. 8, pp. 455–498, 2006.

[15] G. Karsenty, H. M. Kronenberg, and C. Settembre, “Genetic control of bone formation,” Annual Review of Cell and Developmental Biology, vol. 25, pp. 629–648, 2009.

[16] C. R. Jacobs, S. Temiyasathit, and A. B. Castillo, “Osteocyte mechanobiology and pericellular mechanics,” Annual Review of Biomedical Engineering, vol. 12, pp. 369–400, 2010.

[17] L. F. Bonewald, “The amazing osteocyte,” Journal of Bone and Mineral Research, vol. 26, no. 2, pp. 229–238, 2011.

[18] J. J. Nolan, B. Ludvik, P. Beerdens, M. Joyce, and J. Olefsky, “Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone,” New England Journal of Medicine, vol. 331, no. 18, pp. 1188–1193, 1994.

[19] S. L. Suter, J. J. Nolan, P. Wallace, B. Gumbiner, and J. M. Olefsky, “Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects,” Diabetes Care, vol. 15, no. 2, pp. 193–203, 1992.

[20] S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2433, 2006.

[21] Takeda, “Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS® (pioglitazone HCl) tablets for type 2 diabetes mellitus. (Letter to Health Care Providers),” http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153896.pdf, March 2007.

[22] B. Zinman, S. M. Haffner, W. H. Herman et al., “Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 134–142, 2010.

[23] O. P. Lazarenko, S. O. Rzonca, W. R. Hogue, F. L. Swain, L. J. Suva, and B. Lecka-Czernik, “Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone,” Endocrinology, vol. 148, no. 6, pp. 2669–2680, 2007.
[24] A. Grey, “Thiazolidinedione-induced skeletal fragility—mechanisms and implications,” *Diabetes, Obesity and Metabolism*, vol. 11, no. 4, pp. 275–284, 2009.

[25] E. S. Strotmeyer and J. A. Cauley, “Diabetes mellitus, bone mineral density, and fracture risk,” *Current Opinion in Endocrinology, Diabetes and Obesity*, vol. 14, no. 6, pp. 429–435, 2007.

[26] L. R. McCabe, “Understanding the pathology and mechanisms of type 1 diabetic bone loss,” *Journal of Cellular Biochemistry*, vol. 102, no. 6, pp. 1343–1357, 2007.

[27] F. J. de Paula, M. C. Horowitz, and C. J. Rosen, “Novel insights into the relationship between diabetes and osteoporosis,” *Diabetes/Metabolism Research and Reviews*, vol. 26, no. 8, pp. 622–630, 2010.

[28] Y. Hamada, H. Fujii, and M. Fukagawa, “Role of oxidative stress in diabetic bone disorder,” *Bone*, vol. 45, supplement 1, pp. S35–S38, 2009.

[29] P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” *Annual Review of Biochemistry*, vol. 77, pp. 289–312, 2008.

[30] T. Akune, S. Ohba, S. Kamekura et al., “PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” *Journal of Clinical Investigation*, vol. 113, no. 6, pp. 846–855, 2004.

[31] A. A. Ali, R. S. Weinstein, S. A. Stewart, A. M. Parfitt, S. C. Manolagas, and R. L. Jilka, “Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation,” *Endocrinology*, vol. 146, no. 3, pp. 1226–1235, 2005.

[32] B. Lecka-Czernik, I. Gubrij, E. J. Moerman et al., “Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2,” *Journal of Cellular Biochemistry*, vol. 74, no. 3, pp. 357–371, 1999.

[33] S. O. Rzonca, L. J. Suva, D. Gaddy, D. C. Montague, and B. Lecka-Czernik, “Bone is a target for the antidiabetic compound rosiglitazone,” *Endocrinology*, vol. 145, no. 1, pp. 401–406, 2004.

[34] G. Mabilleau, A. Mieczkowska, and M. E. Edmonds, “Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression,” *Diabetic Medicine*, vol. 27, no. 8, pp. 925–932, 2010.

[35] M. A. Sorocéanu, D. Miao, X. Y. Bai, H. Su, D. Goltzman, and A. C. Karaplis, “Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis,” *Journal of Endocrinology*, vol. 183, no. 1, pp. 203–216, 2004.

[36] Y. Wan, L. W. Chong, and R. M. Evans, “PPAR-γ regulates osteoclastogenesis in mice,” *Nature Medicine*, vol. 13, no. 12, pp. 1496–1503, 2007.

[37] W. Wei, X. Wang, M. Yang, L. C. Smith, P. C. Dechow, and Y. Wan, “PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss,” *Cell Metabolism*, vol. 11, no. 6, pp. 503–516, 2010.

[38] W. Wei, D. Zeve, J. M. Suh et al., “Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin,” *Molecular and Cellular Biology*. In press.

[39] J. Feilshchifer, C. Chen, A. Bird, G. R. Mundy, and G. D. Roodman, “Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro,” *Journal of Bone and Mineral Research*, vol. 4, no. 1, pp. 113–118, 1989.

[40] K. Kobayashi, N. Takahashi, E. Jimi et al., “Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction,” *Journal of Experimental Medicine*, vol. 191, no. 2, pp. 275–286, 2000.

[41] J. R. Edwards, S. G. Sun, R. Locklin et al., “LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis,” *Arthritis and Rheumatism*, vol. 54, no. 5, pp. 1451–1462, 2006.

[42] Y. Ishimi, C. Miyaura, C. H. Jin et al., “IL-6 is produced by osteoblasts and induces bone resorption,” *Journal of Immunology*, vol. 145, no. 10, pp. 3297–3303, 1990.

[43] T. Tamura, N. Udagawa, N. Takahashi et al., “Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 90, no. 24, pp. 11924–11928, 1993.

[44] Y. Fujikawa, A. Sabokbar, S. D. Neale, I. Itonaga, T. Torisu, and N. A. Athanasou, “The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-α, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells,” *Bone*, vol. 28, no. 3, pp. 261–267, 2001.

[45] I. Itonaga, A. Sabokbar, S. G. Sun et al., “Transforming growth factor-β induces osteoclast formation in the absence of RANKL,” *Bone*, vol. 34, no. 1, pp. 57–64, 2004.

[46] F. Hemingway, R. Taylor, H. J. Knowles, and N. A. Athanasou, “RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II,” *Bone*, vol. 48, no. 4, pp. 938–944, 2011.

[47] P. D. Home, S. J. Pocock, H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial,” *The Lancet*, vol. 373, no. 9681, pp. 2125–2135, 2009.

[48] S. E. Kahn, B. Zinman, J. M. Lachin et al., “Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT),” *Diabetes Care*, vol. 31, no. 5, pp. 845–851, 2008.

[49] M. Li, L. C. Fan, H. A. Simmons et al., “Surface-specific effects of a PPARγ agonist, darglitazone, on bone in mice,” *Bone*, vol. 39, no. 4, pp. 796–806, 2006.

[50] V. Sottile, K. Seuwen, and M. Kneissel, “Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARα agonist BRL49653 (rosiglitazone),” *Calciified Tissue International*, vol. 75, no. 4, pp. 329–337, 2004.

[51] T. D. Rachner, S. Khosla, and L. C. Hofbauer, “Osteoporosis: now and the future,” *The Lancet*, vol. 377, no. 9773, pp. 1276–1287, 2011.

[52] K. Takagi and A. Kudo, “Bone marrow stromal cell lines having high potential for osteoclast-supporting activity express PPARγ1 and show high potential for differentiation into adipocytes,” *Journal of Bone and Mineral Metabolism*, vol. 26, no. 1, pp. 13–23, 2008.

[53] S. W. Cho, J. Y. Yang, S. J. Her et al., “Osteoblast-targeted overexpression of PPARγ inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice,” *Journal of Bone and Mineral Research*, vol. 26, no. 8, pp. 1939–1952, 2011.

[54] J. S. Park, M. H. Cho, S. J. Nam et al., “Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus,” *European Journal of Endocrinology*, vol. 164, no. 1, pp. 69–74, 2011.
[55] A. Sultan, A. Avignon, F. Galtier et al., “Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients,” Diabetes Care, vol. 31, no. 3, pp. 593–595, 2008.

[56] U. Krause, S. Harris, A. Green et al., “Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 9, pp. 4147–4152, 2010.

[57] S. A. Krum, “Direct transcriptional targets of sex steroid hormones in bone,” Journal of Cellular Biochemistry, vol. 112, no. 2, pp. 401–408, 2011.

[58] W. Wei, D. Zeve, X. Wang et al., “Osteoclast progenitors reside in PPARγ-expressing bone marrow cell population,” Molecular and Cellular Biology. In press.

[59] S. A. Krum, G. A. Miranda-Carboni, P. V. Hauschka et al., “Estrogens protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival,” EMBO Journal, vol. 27, no. 3, pp. 535–545, 2008.

[60] T. Nakamura, Y. Imai, T. Matsumoto et al., “Estrogen prevents bone loss via estrogen receptor α and induction of fas ligand in osteoclasts,” Cell, vol. 130, no. 5, pp. 811–823, 2007.

[61] D. Bilik, L. N. McEwen, M. B. Brown et al., “Thiazolidinediones and fractures: evidence from translating research into action for diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. 4560–4565, 2010.

[62] A. Grey, M. Bolland, G. Gamble et al., “The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 4, pp. 1305–1310, 2007.

[63] S. Benvenuti, I. Cellai, P. Luciani et al., “Androgens and estrogens prevent rosiglitazone-induced adipogenesis in human mesenchymal stem cells,” Journal of Endocrinology Investigation. In press.

[64] D. Seto-Young, D. Aytanski, G. Parikh et al., “Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase,” Hormone and Metabolic Research, vol. 43, no. 4, pp. 250–256, 2011.

[65] J. Lecomte, S. Flamant, S. Salamone et al., “Disruption of Erα signalling pathway by PPARγ agonists: evidences of PPARγ-independent events in two hormone-dependent breast cancer cell lines,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 437–451, 2008.

[66] D. Bonofiglio, S. Gabriele, S. Aquila et al., “Peroxisome proliferator-activated receptor γ activates fas ligand gene promoter inducing apoptosis in human breast cancer cells,” Breast Cancer Research and Treatment, vol. 113, no. 3, pp. 423–434, 2009.

[67] J. M. Vanacker, E. Bonnelle, S. Chopin-Delannoy et al., “Transcriptional activities of the orphan nuclear receptor ERR α (estrogen receptor-related receptor-α),” Molecular Endocrinology, vol. 13, no. 5, pp. 764–773, 1999.

[68] J. M. Vanacker, K. Pettersson, J. A. Gustafsson, and V. Laudet, “Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) α, but not by ERβ,” EMBO Journal, vol. 18, no. 15, pp. 4270–4279, 1999.

[69] R. A. Stein and D. P. McDonnell, “Estrogen-related receptor α as a therapeutic target in cancer,” Endocrine-Related Cancer, vol. 13, supplement 1, pp. S25–S32, 2006.

[70] M. Gallet and J. M. Vanacker, “ERR receptors as potential targets in osteoporosis,” Trends in Endocrinology and Metabolism, vol. 21, no. 10, pp. 637–641, 2010.

[71] K. A. Ishii, T. Fumoto, K. Iwai et al., “Coordination of PGC-1β and iron uptake in mitochondrial biogenesis and osteoclast activation,” Nature Medicine, vol. 15, no. 3, pp. 259–266, 2009.

[72] K. K. Ryan, B. Li, B. E. Grayson et al., “A role for central nervous system PPAR-γ in the regulation of energy balance,” Nature Medicine, vol. 17, no. 5, pp. 623–626, 2011.

[73] K. M. Nicks, T. W. Fowler, and D. Gaddy, “Reproductive hormones and bone,” Current Osteoporosis Reports, vol. 8, no. 2, pp. 60–67, 2010.

[74] V. Seifert-Klaus and J. C. Prior, “Progesterone and bone: actions promoting bone health in women,” Journal of Osteoporosis, vol. 2010, Article ID 845180, 2010.

[75] D. Schramek, A. Leibbrandt, V. Sigl et al., “Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer,” Nature, vol. 468, no. 7320, pp. 98–102, 2010.

[76] P. Wang, N. Dharmaraj, M. J. Brayman, and D. D. Carson, “Peroxisome proliferator-activated receptor γ activation inhibits progesterone-stimulated human MUC1 expression,” Molecular Endocrinology, vol. 24, no. 7, pp. 1368–1379, 2010.

[77] N. Ling, S. Y. Ying, and N. Ueno, “Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin,” Nature, vol. 321, no. 6072, pp. 779–782, 1986.

[78] K. M. Nicks, D. S. Perrien, N. S. Akel, L. J. Suva, and D. Gaddy, “Regulation of osteoosteogenesis in osteoclastogenesis by the other reproductive hormones, Activin and Inhibin,” Molecular and Cellular Endocrinology, vol. 310, no. 1–2, pp. 11–20, 2009.

[79] S. Hirai, M. Yamanaka, H. Kawachi, T. Matsui, and H. Yano, “Activin A inhibits differentiation of 3T3-L1 preadipocyte,” Molecular and Cellular Endocrinology, vol. 232, no. 1–2, pp. 21–26, 2005.

[80] B. M. Necela, W. Su, and E. A. Thompson, “Peroxisome proliferator-activated receptor γ down-regulates follistatin in intestinal epithelial cells through SPI,” Journal of Biological Chemistry, vol. 283, no. 44, pp. 29784–29794, 2008.

[81] P. R. Ebeling, L. M. Atley, J. R. Guthrie et al., “Bone turnover markers and bone density across the menopausal transition,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 9, pp. 3366–3371, 1996.

[82] M. R. Sowers, J. S. Finkelstein, B. Ettinger et al., “The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN,” Osteoporosis International, vol. 14, no. 1, pp. 44–52, 2003.

[83] M. R. Sowers, G. A. Greendale, I. Bondarenko et al., “Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN,” Osteoporosis International, vol. 14, no. 3, pp. 191–197, 2003.

[84] L. Sun, Y. Peng, A. C. Sharrow et al., “FSH directly regulates bone mass,” Cell, vol. 125, no. 2, pp. 247–260, 2006.

[85] M. T. Drake, L. K. McCready, K. A. Hoey, E. J. Atkinson, and S. Khosla, “Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 11, pp. 5063–5068, 2010.

[86] C. M. Allan, R. Kalak, C. R. Dunstan et al., “Follicle-stimulating hormone increases bone mass in female mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 52, pp. 22629–22634, 2010.
[87] F. Bogazzi, D. Russo, M. T. Locci et al., “Peroxisome proliferator-activated receptor (PPAR)γ is highly expressed in normal human pituitary gland,” Journal of Endocrinological Investigation, vol. 28, no. 10, pp. 899–904, 2005.

[88] S. Sharma, P. M. Sharma, D. S. Mistry et al., “PPARG regulates gonadotropin-releasing hormone signaling in LβT2 cells in vitro and pituitary gonadotroph function in vivo in mice,” Biology of Reproduction, vol. 84, no. 3, pp. 466–475, 2011.

[89] A. P. Heaney, M. Fernando, and S. Melmed, “PPAR-γ receptor ligands: novel therapy for pituitary adenomas,” Journal of Clinical Investigation, vol. 111, no. 9, pp. 1381–1388, 2003.

[90] C. Elabd, A. Basillais, H. Beaupied et al., “Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis,” Stem Cells, vol. 26, no. 9, pp. 2399–2407, 2008.

[91] S. Colucci, G. Colaianni, G. Mori, M. Grano, and A. Zallone, “Human osteoclasts express oxytocin receptor,” Biochemical and Biophysical Research Communications, vol. 297, no. 3, pp. 442–445, 2002.

[92] R. Tamma, G. Colaianni, L. L. Zhu et al., “Oxytocin is an anabolic bone hormone,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 17, pp. 7149–7154, 2009.

[93] M. Eckertova, M. Ondrejcakova, K. Krskova, S. Zorad, and D. Jezova, “Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis,” British Journal of Pharmacology, vol. 162, no. 2, pp. 452–463, 2011.

[94] D. Seriwatanachai, K. Thongchote, N. Charoenphandhu et al., “Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor κB ligand/osteoprotegerin ratio,” Bone, vol. 42, no. 3, pp. 535–546, 2008.

[95] R. Nanbu-Wakao, Y. Fujitani, Y. Masuho, M. A. Muramatu, and H. Wakao, “Prolactin enhances CCAAT enhancer-binding protein-β (C/EBPβ) and peroxisome proliferator-activated receptor γ (PPARγ) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells,” Molecular Endocrinology, vol. 14, no. 2, pp. 307–316, 2000.

[96] A. Gruszka, J. Kunert-Radek, and M. Pawlikowski, “Rosiglitazone, PPAR-γ receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro,” Neuroendocrinology Letters, vol. 26, no. 1, pp. 51–54, 2005.

[97] B. Lecka-Czernik, “Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis,” Current Osteoporosis Reports, vol. 8, no. 4, pp. 178–184, 2010.

[98] O. P. Lazarenko, S. O. Rzonca, L. J. Suva, and B. Lecka-Czernik, “Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat,” Bone, vol. 38, no. 1, pp. 74–84, 2006.

[99] J. H. Choi, A. S. Banks, J. L. Estall et al., “Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ3 by Cdk5,” Nature, vol. 466, no. 7305, pp. 451–456, 2010.

[100] G. Derosa and P. Maffioli, “Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 91, no. 3, pp. 265–270, 2011.